ArticleEuropean journal of nuclear medicine and molecular imaging2022
PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Therapeutic potential of diosgenin in hepatocellular carcinoma through molecular mechanisms and nanodelivery strategies.Discover oncology · 2026Review
- Arsenic sulfide alleviates the progression of liver cancer malignancy by inhibiting the expression of TLCD1 in mice.BMC medical genomics · 2025Article
- Patient-derived xenograft model: Applications and challenges in liver cancer.Chinese medical journal · 2025Review
- Prostate-specific membrane antigen-targeting radiopharmaceuticals: a new frontier in hepatic malignancies.Frontiers in oncology · 2025Review
- 18F-5-fluoro-aminosuberic acid PET/CT imaging of oxidative-stress features during the formation of DEN-induced rat hepatocellular carcinoma.Theranostics · 2025Article
- [Current status and new advancements in molecular imaging of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- "One Method to Label Them All": A Single Fully Automated Protocol for GMP-CompliantCurrent radiopharmaceuticals · 2024Article
- Tungsten-based nanoparticles as contrast agents for liver tumor detection using dual-energy computed tomography.Biomaterials science · 2023Article
- Demonstration of therapy response to radioembolization withEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.Cancers · 2023Review
- A case of well-differentiated hepatocellular carcinoma detected withQuantitative imaging in medicine and surgery · 2023Article
- Preclinical evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- [European journal of nuclear medicine and molecular imaging · 2023Article
- Comparison between PSMA PET/CT and MRI for CharacterizingTomography (Ann Arbor, Mich.) · 2023Article
- Emerging theragnostic radionuclide applications for hepatocellular carcinoma.Frontiers in nuclear medicine · 2023Review
- The era of prostate-specific membrane antigen (PSMA)-based theranostics for hepatocellular carcinoma is upcoming: are we ready for it?European journal of nuclear medicine and molecular imaging · 2022Article
- PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers.European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
objectiveHepatocellular carcinoma (HCC) is a malignant tumor associated with high morbidity and mortality rates. In many non-prostate solid tumors such as HCC, prostate-specific membrane antigens (PSMA) are overexpressed in tumor-associated endothelial cells. Therefore, the aim of this study was to evaluate the performance of [
methods[
resultsLow PSMA expression level of HepG2 and HuH-7 cells was observed, and the cellular uptake and blocking study confirmed the non-specificity of the PSMA-targeted probe binding to HepG2 and HuH-7 cells. In the subcutaneous xenograft models, the tumor uptakes at 0.5 h were 0.76 ± 0.12%ID/g (HepG2 tumors) and 0.78 ± 0.08%ID/g (HuH-7 tumors), respectively, which were significantly higher than those of the blocking groups (0.23 ± 0.04%ID/g and 0.20 ± 0.04%ID/g, respectively). In the orthotopic xenograft models, PET images clearly displayed the tumor locations based on the preferential accumulation of [
conclusionIn this study, in vivo PET on different types of HCC xenograft models illustrated high uptake within tumors, which confirmed that [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.